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Summary. Recent biochemical and genetic studies have 
substantially increased our understanding of death signal 
transduction pathways, making it clear however, that 
apoptosis is not a single-lane, one-way street. Rather, 
multiple parallel pathways have been identified. For 
instance, analysis of bcl-2, bax, p53, and caspase 
knockout mice while establishing distinct roles for each 
of these apoptotic players, they also provided valuable 
information for the design of specific inhibitors of 
apoptosis. Thus blocking one pathway, as in caspase 
knockout mice, what we observe is not a complete 
suppression of apoptosis but rather a delay in apoptosis 
induction (Hakem et al., 1998; Kuida et al., 1998). In 
view of nature's means of ensuring activation of a 
compensatory apoptotic response, when one pathway 
fails in developing prostate cancer therapeutic 
interventions, the challenge remains to further dissect 
individual apoptotic pathways. Advances in our 
understanding of the integrated functions governing 
prostate cell proliferation and cell death, clearly suggest 
that effective prostate cancer therapies are not only 
molecularly targeted, but that are also customized to take 
into account the delicate balance of opposing growth 
influences in the ageing gland. In this review we discuss 
the evidence on the significance of molecular 
deregulation of the key players of this growth 
equlibrium, apoptosis and cell proliferation in prostate 
cancer progression, and the clinical implications of 
changes in the apoptotic response in disease detection 
and therapy. 
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Introduction 
Prostate cancer threatens to become an American 
epidemic accounting for an estimated 37,000 fatalities in 
1999 (Landis et al., 1999). It is the leading male 
malignancy in the United States, superceding the once 
prevalent lung cancer status (Landis et al., 1999). 
Prostate cancer mortality results from metastasis to the 
bone and lymph nodes and progression from androgen- 
dependent to androgen-independent prostatic growth 
(Isaacs et al., 1994). Radical prostatectomy, androgen- 
ablation therapy and radiotherapy are considered 
curative for localized disease, however, no treatment for 
metastatic prostate cancer is available that effectively 
increases patient survival (Raghavan, 1988; Crawford, 
1989; Lezefsky et al., 1994). 
Induction of apoptosis represents a powerful weapon 
against advanced prostate cancer. The therapeutic 
significance of apoptosis in the treatment of prostate 
cancer stems from evidence demonstrating that like 
normal prostate epithelia1 cells, prostate cancer cells in 
androgen-dependent tumors undergo apoptosis in 
response to androgen deprivation (Kyprianou and Isaacs, 
1988; Kyprianou et al., 1990). A similar apoptotic 
pathway of cell  destruction can be activated by 
chemotherapeutic drugs or ionizing irradiation in 
androgen-independent prostate cancer cells (Sklar et al., 
1993; Furuya et al., 1994; Kyprianou et al., 1994; 
Palayoor et al., 1997). Compelling evidence from several 
investigators suggests that the tumorigenic growth of the 
prostate depends on the evasion of the normal 
homeostatic control mechanisms, where cell  
proliferation exceeds cell death (Berges et al., 1995; Tu 
et al. ,  1996).  A general understanding of how 
cell proliferation and cell  death are regulated by 
extracellular signals requires the identification of 
mechanisms underlying these processes. Additionally, 
pharmacological manipulation or genetic targeting of the 
major apoptosis regulators, such as the bcl-2 and caspase 
family of proteins, represent clinically attractive avenues 
for exploring effective therapeutic strategies for prostate 
cancer. Since cell proliferation follows an orderly 












